{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:56Z","timestamp":1772120036372,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01396-z","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:22:30Z","timestamp":1768296150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan"],"prefix":"10.1007","volume":"57","author":[{"given":"Yoshinori","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobue","family":"Futawatari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneharu","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidejiro","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jmedgenet-2016-104171","volume":"54","author":"X-Y Zhang","year":"2016","unstructured":"Zhang X-Y, Zhang P-Y. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2016;54:305\u201312. https:\/\/doi.org\/10.1136\/jmedgenet-2016-104171.","journal-title":"J Med Genet"},{"key":"1396_CR2","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing Irinotecan with Paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u2013444. https:\/\/doi.org\/10.1200\/JCO.2012.48.5805.","journal-title":"J Clin Oncol"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Cutsem EV, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"key":"1396_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5.","journal-title":"Lancet"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1396_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"1396_CR7","doi-asserted-by":"publisher","unstructured":"Poole RM, Vaidya A, Ramucirumab. First global approval. Drugs. 2014;74:1047\u20131058. https:\/\/doi.org\/10.1007\/s40265-014-0244-2","DOI":"10.1007\/s40265-014-0244-2"},{"key":"1396_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0.","journal-title":"Lancet Oncol"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim J-H, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, P\u00e9rol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(14)60845-X.","journal-title":"Lancet"},{"key":"1396_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","volume":"99","author":"K Yoh","year":"2016","unstructured":"Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016;99:186\u201393. https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.019.","journal-title":"Lung Cancer"},{"key":"1396_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5.","journal-title":"Lancet Oncol"},{"key":"1396_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9.","journal-title":"Lancet Oncol"},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10120-018-0811-4","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Fujitani K, Nagashima F, Omuro Y, Machida N, Nishina T, Koue T, Tsujimoto M, Maeda K, Satoh T. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. Gastric Cancer. 2018;21:1041\u20139. https:\/\/doi.org\/10.1007\/s10120-018-0811-4.","journal-title":"Gastric Cancer"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jgh.14007","volume":"33","author":"K Muro","year":"2018","unstructured":"Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Santos LVD, et al. Age does not influence efficacy of ramucirumab in advanced gastric cancer: subgroup analyses of REGARD and RAINBOW. J Gastroenterol Hepatol. 2018;33:814\u201324. https:\/\/doi.org\/10.1111\/jgh.14007.","journal-title":"J Gastroenterol Hepatol"},{"key":"1396_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.21037\/tlcr-20-1263","volume":"10","author":"K Matsumoto","year":"2021","unstructured":"Matsumoto K, Tamiya A, Matsuda Y, Taniguchi Y, Atagi S, Kawachi H, Tamiya M, Tanizaki S, Uchida J, Ueno K, Yanase T, Suzuki H, Hirashima T. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res. 2021;10:1642\u201352. https:\/\/doi.org\/10.21037\/tlcr-20-1263.","journal-title":"Transl Lung Cancer Res"},{"key":"1396_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5230\/jgc.2023.23.e15","volume":"23","author":"T Ogata","year":"2023","unstructured":"Ogata T, Narita Y, Wainberg ZA, Cutsem EV, Yamaguchi K, Piao Y, Zhao Y, Peterson PM, Wijayawardana SR, Abada P, Chatterjee A, Muro K. Exploratory analysis of patients with gastric\/gastroesophageal junction adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study. J Gastric Cancer. 2023;23:289\u2013302. https:\/\/doi.org\/10.5230\/jgc.2023.23.e15.","journal-title":"J Gastric Cancer"},{"key":"1396_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10120-018-0796-z","volume":"21","author":"AS Paulson","year":"2018","unstructured":"Paulson AS, Hess LM, Liepa AM, Cui ZL, Aguilar KM, Clark J, et al. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer. 2018;21:831\u201344. https:\/\/doi.org\/10.1007\/s10120-018-0796-z.","journal-title":"Gastric Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01396-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:20:15Z","timestamp":1768342815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01396-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01396-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6902358\/v1","asserted-by":"object"}]},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Faculty of Medicine, Toho University (Date: April 19, 2023; No.: A22081_A21036_A22071_A22043_A20007_A19017_A16084 and Date: May 30, 2023; M23008).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Information about the study was made available on the institutional website, allowing potential participants to opt-out.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}